Empowering Healthcare Decisions
Right at the point of Care

A 71-year-old woman, previously well, presented with a 3-month history of bilat­eral lower-limb rash. Initial blood test on 22 December 2023 showed leukocytosis with white blood cell (WBC) count 17.8 x 109/L, haemoglobin 10.3 g/dL and plate­lets 172 x 109/L. Peripheral blood analysis found 14 percent blast cells and marked monocytosis (15 percent). She was ad­mitted for further evaluation.

Relaxed prescription requirements for add-on sodium-glucose cotransporter 2 inhibitors (SGLT2i) now allow earlier use of these cardiorenal-protective therapies in eligible patients as the second antidiabetic medication after metformin. Dr Paul Lee and Dr David Lui, Specialists in Endocrinology, Diabetes & Metabolism in Hong Kong, discussed how changes in SGLT2i prescription requirements may benefit patients with type 2 diabetes (T2D) who have chronic kidney disease (CKD) or established cardiovascular disease (CVD), and the role of SGLT2i (eg, empagliflozin) in cardiovascular-kidney-metabolic (CKM) syndrome management.

Lazertinib film-coated tablet 80 mg and 240 mg